IL1B and mevalonic aciduria: A lot of studies focus on the pathogenic role of the inflammasome – IL-1 axis in these SAIDs, and many patients have good responses to IL-1-blocking agents (e.g. anakinra, canakinumab, and rilonacept), although some patients with FMF, TRAPS or HIDS are less responsive to IL-1 inhibition (7, 8; 9–15).